| Authors: |
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. fravandi@mdanderson.org., Roboz GJ; Weill Cornell Medicine, New York, NY, USA.; New York Presbyterian Hospital, New York, NY, USA., Wei AH; Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia.; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia., Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Pocock C; Kent & Canterbury Hospital, Canterbury, UK., Selleslag D; AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., Sayar H; Indiana University Cancer Center, Indianapolis, IN, USA., Musso M; La Maddalena - Casa di Cura, Palermo, Italy., Figuera-Alvarez A; Hospital Universitario de La Princesa, Madrid, Spain., Safah H; Tulane University Health Science Center, New Orleans, LA, USA., Tse W; University of Louisville School of Medicine, Louisville, KY, USA., Sohn SK; Kyungpook National University Hospital, Daegu, Korea., Hiwase D; Royal Adelaide Hospital, Adelaide, Australia., Chevassut T; Brighton and Sussex Medical School, Brighton, UK., Pierdomenico F; Portuguese Institute of Oncology Lisbon, Lisbon, Portugal., La Torre I; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland., Skikne B; University of Kansas Medical Center, Kansas City, KS, USA.; Bristol Myers Squibb, Princeton, NJ, USA., Bailey R; Bristol Myers Squibb, Princeton, NJ, USA., Zhong J; Bristol Myers Squibb, Princeton, NJ, USA., Beach CL; Bristol Myers Squibb, Princeton, NJ, USA., Dombret H; Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.; Institut de Recherche Saint-Louis, Université de Paris, Paris, France. |
